Market Signal Briefing

Original U.Today article

Sat, 18/10/2025 - 16:49

Can traders expect Bitcoin (BTC) to test the $100,000 mark next week?

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Buyers are trying to seize the initiative on Saturday, according to CoinStats.

Top coins by CoinStats BTC/USDThe rate of Bitcoin (BTC) has risen by 1.11% since yesterday.

Image by TradingViewOn the hourly chart, the price of BTC is far from the support and resistance levels. The volume is low, which means traders are unlikely to witness increased volatility by tomorrow.

Image by TradingViewOn the bigger time frame, there are no reversal signals so far. In this regard, one should pay attention to yesterday's bar low of $103,530.

You Might Also Like

If bulls lose it, the decline may continue to the $100,000 area.

Image by TradingViewFrom the midterm point of view, sellers are also more powerful than buyers. If a breakout of the $100,426 support happens, the accumulated energy might be enough for a move to the $95,000 zone.

Bitcoin is trading at $106,909 at press time.

Related articles

North Korean threat actors have adopted a blockchain-based technique called EtherHiding to deliver malware designed to steal cryptocurrency including XRP.

Summary

Hackers embed malicious code in smart contracts to steal XRP and other crypto.
EtherHiding evades takedowns by hosting malware on decentralized blockchains.
Fake recruiters trick developers into installing malware during job interviews.

According to Google’s Threat Intelligence Group, this is the first time GTIG has observed a nation-state actor using this method.

The method embeds malicious JavaScript payloads inside blockchain smart contracts to create resilient command-and-control servers.

The EtherHiding technique targets developers in cryptocurrency and technology sectors through social engineering campaigns tracked as “Contagious Interview.”

The campaign has led to numerous cryptocurrency heists affecting XRP (XRP) holders and users of other digital assets.

Blockchain-based attack infrastructure evades detection
EtherHiding stores malicious code on decentralized and permissionless blockchains and removes central servers that law enforcement or cybersecurity firms can take down.

Attackers controlling smart contracts can update malicious payloads at any time and maintain persistent access to compromised systems.

Security researchers can tag contracts as malicious on blockchain scanners like BscScan, but malicious activity continues regardless of these warnings.

Google’s report describes EtherHiding as a “shift towards next-generation bulletproof hosting” where blockchain technology features enable malicious purposes.

When users interact with compromised sites, the code activates to steal XRP, other cryptocurrencies, and sensitive data.

The compromised websites communicate with blockchain networks using read-only functions that avoid creating ledger transactions. This minimizes detection and transaction fees.

Sophisticated social engineering
The Contagious Interview campaign centers on social engineering tactics that mimicks legitimate recruitment processes through fake recruiters and fabricated companies.

Fake recruiters lure candidates onto platforms like Telegram or Discord, then deliver malware through deceptive coding tests or fake software downloads disguised as technical assessments.

The campaign employs multi-stage malware infection, including JADESNOW, BEAVERTAIL, and INVISIBLEFERRET variants affecting Windows, macOS, and Linux systems.

Victims believe they’re participating in legitimate job interviews while unknowingly downloading malware designed to gain persistent access to corporate networks and steal cryptocurrency holdings.

19h30 ▪
4
min read ▪ by
Fenelon L.

Summarize this article with:

DeFi Development Corp. has just reached a new milestone. The Nasdaq-listed company has injected an additional 16 million dollars into its Solana reserves, thus consolidating its position among the largest institutional holders of the SOL crypto.

In brief

DeFi Development Corp. has just acquired 86,307 additional SOL tokens for 16 million dollars, at an average price of $110.91 per unit.
The company’s total reserves now exceed 2 million SOL, valued at around 426 million dollars.
This operation positions DeFi Development among the top five largest public Solana holders, although Forward Industries maintains the top spot with nearly 7 million tokens.

Development continues to invest massively in Solana
DeFi Development Corp. does not hide its ambitions. The company listed under the ticker DFDV has just announced the acquisition of 86,307 SOL tokens bringing its holdings to more than 2 million tokens. 

This operation, carried out at an average price of 110.91 dollars per unit, represents an investment of 16 million dollars and increases the company’s reserves by nearly 5%.

This massive accumulation strategy recalls that of MicroStrategy with bitcoin, but applied to the Solana ecosystem. The company founded this year by former Kraken executives is betting everything on the blockchain known for its speed and low fees.

With about 28 million shares outstanding, DeFi Development now displays a ratio of 14.67 dollars of SOL per share, a figure down from the 19.44 dollars recorded in September when the company had 25 million shares.

This dilution of shares raises questions. Investors must wonder whether this rapid expansion of the share capital may dilute value for existing shareholders, despite the increase in SOL reserves. 

A unique positioning but fierce competition
DeFi Development does not just buy and hold tokens. The company also deploys a staking strategy on various assets within the Solana ecosystem, including memecoins like Dogwifhat. 

It also generates additional revenue through its validation services, notably for Kraken, the crypto exchange from which its founders come.

This diversification of activities is an undeniable asset. By combining reserve accumulation and operational revenue generation, DeFi Development aims to create a more resilient business model than simple “treasury companies” that only hold cryptos.

However, competition remains fierce. While DeFi Development ranks among the top five largest public Solana holders, it is still far from Forward Industries (ticker FORD), the undisputed leader. 

This company, backed by heavyweights like Galaxy, Jump Crypto, and Multicoin Capital, holds nearly 7 million SOL. A figure that alone exceeds the combined reserves of the next three companies.

This domination by Forward Industries raises a crucial question: can the market support several large “Solana treasuries” without causing excessive concentration? The answer will likely determine the long-term success of companies like DeFi Development.

DeFi Development continues its aggressive accumulation of Solana but navigates still uncharted waters. While the strategy may pay off if the SOL price soars, it also exposes the company to the inherent risks of crypto volatility.

Only the future will tell if this bold bet will turn DeFi Development into a major player in the blockchain economy or simply a victim of an unpredictable market.

Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.

Join the program

A

A

Lien copié

Fenelon L.

Passionné par le Bitcoin, j'aime explorer les méandres de la blockchain et des cryptos et je partage mes découvertes avec la communauté. Mon rêve est de vivre dans un monde où la vie privée et la liberté financière sont garanties pour tous, et je crois fermement que Bitcoin est l'outil qui peut rendre cela possible.

DISCLAIMER

The views, thoughts, and opinions expressed in this article belong solely to the author, and should not be taken as investment advice. Do your own research before taking any investment decisions.

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

TrueCar, Inc. (NASDAQ: TRUE)’s sale to Fair Holdings, Inc., an entity led by TrueCar founder Scott Painter, for $2.55 per share. If you are a TrueCar shareholder, click here to learn more about your legal rights and options.

Hillenbrand, Inc. (NYSE: HI)’s sale to an affiliate of Lone Star Funds for $32.00 per share in cash. If you are a Hillenbrand shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]  
https://www.halpersadeh.com

Analyst’s Disclosure:I/we have a beneficial long position in the shares of T.PR.C either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I am also writing (out of the money) put options on AT&T.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

On October 17, 2025, Oak Harvest Investment Services, a division of Oak Harvest Financial Group, disclosed a new position in Verizon Communications (VZ 0.48%), acquiring shares valued at approximately $10.7 million in Q3 2025.

IMAGE SOURCE: VERIZON.

What happenedAccording to a filing with the U.S. Securities and Exchange Commission dated October 17, 2025, Oak Harvest Investment Services initiated a new position in Verizon Communications, purchasing approximately 243,369 shares. The estimated transaction value, based on the average price in Q3 2025, was $10.7 million. As this was an initial investment, Oak Harvest's reported total holdings in Verizon were also $10.7 million.

What else to knowThis new position accounts for 1.2% of Oak Harvest Investment Services' $857.35 million in 13F reportable assets as of September 30, 2025, placing it outside the top five holdings.

Top holdings after the filing:

VGSH: $51.76 million (6.0% of AUM) as of September 30, 2025VOO: $44.57 million (5.2% of AUM) as of September 30, 2025AAPL: $34.54 million (4.0% of AUM) as of September 30, 2025VYM: $25.39 million (3.0% of AUM) as of September 30, 2025JPM: $23.36 million (2.7% of AUM) as of September 30, 2025As of October 17, 2025, Verizon Communications shares were priced at $40.55, down 7.8% over the past year, underperforming the S&P 500 by 21.6 percentage points during the same period.

Company OverviewMetricValueRevenue (TTM)$137.00 billionNet Income (TTM)$18.19 billionDividend Yield6.81%Price (as of market close October 17, 2025)$40.55Company SnapshotVerizon Communications is a leading provider of telecommunications and technology services with a diversified portfolio spanning consumer and business segments. The company leverages its extensive network infrastructure to deliver connectivity, digital services, and managed solutions at scale.

The company provides wireless and wireline communications, internet access, video, voice services, and network solutions to consumers, businesses, and government entities worldwide.

Verizon generates revenue through subscription-based service plans, equipment sales, and network access fees from both consumers and business clients.

Foolish takeOak Harvest Investment Services buying Verizon shares is noteworthy because of its decision to begin a position in the beleaguered stock. A confluence of factors could be driving the decision to invest in the telecommunications giant at this time.

Despite tough competition in the industry, Verizon grew Q2 revenue by 5% year over year to $34.5 billion. The company also ended the first half of 2025 with free cash flow (FCF) of $8.8 billion, an increase from 2024's $8.5 billion.

This led Verizon to raise its FCF outlook for the year to between $19.5 billion to $20.5 billion. FCF is a key factor in the company's ability to pay its robust dividend.

Speaking of which, the dividend could have been another contributor to Oak Harvest taking a stake in Verizon. After all, the yield is currently an impressive 6.8%.

The juicy dividend yield combines with Verizon's attractive price-to-earnings ratio of around 9 to make the company's stock a compelling investment. These factors also mean it's a good time to buy Verizon shares, especially for income investors.

Glossary13F reportable assets: Assets that investment managers must disclose quarterly to the SEC if they exceed a certain threshold.
Assets under management (AUM): The total market value of investments managed on behalf of clients by a financial institution or fund.
Position: The amount of a particular security or asset held by an investor or fund.
Stake: The ownership interest or share held in a company or asset.
Dividend Yield: A financial ratio showing how much a company pays in dividends each year relative to its stock price.
Top holdings: The largest investments in a fund or portfolio, typically ranked by value or percentage of total assets.
Subscription-based service plans: Recurring payment models where customers pay regularly for ongoing access to a service.
TTM: The 12-month period ending with the most recent quarterly report.

JPMorgan Chase is an advertising partner of Motley Fool Money. Robert Izquierdo has positions in Apple, JPMorgan Chase, and Verizon Communications. The Motley Fool has positions in and recommends Apple, JPMorgan Chase, Vanguard S&P 500 ETF, and Vanguard Whitehall Funds - Vanguard High Dividend Yield ETF. The Motley Fool recommends Verizon Communications. The Motley Fool has a disclosure policy.

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025.

SO WHAT: If you purchased aTyr Pharma common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Johnson & Johnson Today

JNJ

Johnson & Johnson

$193.26 +1.15 (+0.60%)

As of 10/17/2025 03:59 PM Eastern

This is a fair market value price provided by Polygon.io. Learn more.

52-Week Range$140.68▼

$194.40Dividend Yield2.69%

P/E Ratio18.65

Price Target$199.59

Recent market speculation linking Johnson & Johnson NYSE: JNJ to a complete acquisition of its partner, Protagonist Therapeutics NASDAQ: PTGX, offers a valuable glimpse into a core corporate strategy. For a healthcare sector giant of Johnson & Johnson's scale, such moves are not about chasing short-term stock pops. They are a fundamental part of a long-term playbook designed to systematically acquire innovation, fuel future growth, and deliver reliable shareholder value.

Understanding this disciplined strategy is key to understanding the company’s future and why many investors are looking past near-term headwinds.

Get Johnson & Johnson alerts:

Trimming the Fat, Fueling the Future
The foundation of Johnson & Johnson’s acquisition strategy is an active and continuous reshaping of its entire portfolio. This is more than buying new companies; it is about strategically divesting slower-growth assets to unlock capital and management focus for redeployment into higher-growth opportunities.

The 2023 spinoff of the Kenvue NYSE: KVUE consumer health business was the first significant step. The recently announced plan to separate the Orthopedics business, a division that generated approximately $9.2 billion in 2024 sales, is the next step in the company's strategy.

This strategic pruning provides Johnson & Johnson with immense financial firepower to pursue external innovation. The company’s financial health, demonstrated by the generation of approximately $14 billion in free cash flow in the first three quarters of 2025, is fuel for its acquisition engine.

For investors, the message is clear: management is actively steering the company away from lower-margin businesses to concentrate its resources on the high-stakes, high-reward frontiers of medicine and technology.

How Recent Deals Are Already Paying Off
Johnson & Johnson’s strategy has a proven track record of delivering tangible results that are already boosting the bottom line. Recent MedTech and Innovative Medicine acquisitions show how effectively the company can identify, acquire, and integrate high-value assets to drive immediate growth.

Supercharging MedTech: The acquisitions of Abiomed and Shockwave Medical have transformed Johnson & Johnson's MedTech segment. These deals are a primary reason the Cardiovascular unit has become a standout performer, posting an impressive 11.6% operational growth in the third quarter of 2025 earnings report. This success is turning what was once a steady business into a high-growth engine, validating the company's capital deployment strategy.
Bolstering the Pharma Pipeline: The recent acquisition of Intra-Cellular Therapies brought the key asset CAPLYTA into the pharmaceutical portfolio. The drug is already a significant contributor, delivering $240 million in sales in the third quarter alone and demonstrating healthy sequential growth. Management now cites it as a primary driver for the Neuroscience franchise, showcasing how quickly an acquisition can become a core part of the growth story.

These examples demonstrate a clear pattern: Johnson & Johnson is not just making deals but making the right deals in the right markets and executing them effectively.

The J&J Method: Partner, Validate, Acquire
Johnson & Johnson Stock Forecast Today12-Month Stock Price Forecast:
$199.59
3.27% Upside

Moderate Buy
Based on 22 Analyst Ratings

Current Price$193.27High Forecast$215.00Average Forecast$199.59Low Forecast$153.00Johnson & Johnson Stock Forecast Details

The potential Protagonist acquisition is a perfect, real-time case study of the company’s disciplined M&A playbook. This is not a speculative move on an unknown technology but the logical culmination of a long-term, successful partnership.

Johnson & Johnson has collaborated with Protagonist for years to develop icotrokinra, a first-in-class oral peptide for treating immune-mediated diseases. That partnership has been exceptionally fruitful. Icotrokinra is now a significant asset in Johnson & Johnson’s late-stage pipeline, recently submitted to the FDA for approval in plaque psoriasis.

The drug has also demonstrated superiority to a key competitor, deucravacitinib, in head-to-head clinical trials and posted positive new data in ulcerative colitis.

This partner, validate, then acquire approach is a highly disciplined form of M&A that de-risks the investment for shareholders. It allows Johnson & Johnson to confirm an asset's clinical potential before committing the much larger capital required for a complete acquisition.

The rumored deal represents a strategic move to gain full ownership of a highly promising, clinically validated asset that Johnson & Johnson already knows intimately, thereby maximizing the probability of a triumphant return on investment.

Growth, Income, and a De-Risked Future
For long-term, conservative investors, Johnson & Johnson's M&A strategy is the engine that drives the company’s entire value proposition. It provides a clear and effective method for ensuring future growth and its unwavering commitment to shareholder returns.

Johnson & Johnson Dividend PaymentsDividend Yield2.69%

Annual Dividend$5.20

Dividend Increase Track Record64 Years

Dividend Payout Ratio50.19%

Next Dividend PaymentDec. 9

JNJ Dividend History

This disciplined acquisition strategy is the company's primary tool for offsetting major headwinds, like the ongoing patent cliff for its multi-billion-dollar drug, Stelara. The company creates a more durable and predictable long-term growth trajectory by consistently adding new, high-growth revenue streams through well-vetted deals. 

This confidence was echoed on the Q3 earnings call, where management stated they do not need large M&A to deliver on the high end of their growth targets, reinforcing the strength of their current pipeline and bolt-on strategy. The stock's long-term strength is further reinforced by a positive technical assessment from market analysts, who observe a sustained multi-year uptrend establishing a robust base for potential price growth.

Ultimately, this success directly funds Johnson & Johnson's coveted Dividend King status. The strong cash flows generated by these successfully integrated acquisitions enable the company to fund its annual $5.20 per share dividend and deliver 64 consecutive years of increases.

For income-focused investors who are eyeing the company's attractive 2.73% yield, the M&A playbook is the engine that secures the dividend's future, ensuring the company remains a cornerstone of a stable, long-term portfolio.

Should You Invest $1,000 in Johnson & Johnson Right Now?Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

CHENNAI, India, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Sify Technologies Limited (NASDAQ: SIFY), India’s leading Digital ICT solutions provider with global service capabilities spanning Data Center, Cloud, Networks, Security and Digital services, today announced that it will report its unaudited IFRS financial results for the second quarter ended September 30, 2025 on Saturday, October 25, 2025 before the market opens. 

The following Monday, October 27, 2025, Sify will host a conference call at 8:30 AM ET with Mr. Raju Vegesna, Chairman of the Board and Mr. M P Vijay Kumar, Executive Director & Group CFO. Interested parties may participate by dialling +1-888-506-0062 (Toll Free in the U.S. or Canada) or +1-973-528-0011 (International), which will also be simultaneously broadcast live over the Internet at www.sifytechnologies.com/investors or https://www.webcaster4.com/Webcast/Page/2184/53133.

Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast.

The online archive of the Webcast will be available shortly after the conference call. Investors can also listen to the replay by dialling +1-877-481-4010 (Toll Free in the U.S. or Canada) or +1-919-882-2331 (International) and entering the replay passcode 53133. Please allow for some time post conference call to access the archive of the Webcast. The replay is available until November 03, 2025.

About Sify Technologies

A multiple times Golden Peacock award winner for Corporate Governance, Sify Technologies is India’s most comprehensive ICT service & solution provider. With Cloud at the core of our solutions portfolio, Sify is focussed on the changing ICT requirements of the emerging Digital economy and the resultant demands from large, mid and small-sized businesses. 

Sify’s infrastructure comprising state-of-the-art data centers, the largest MPLS network, partnership with global technology majors and deep expertise in business transformation solutions modelled on the cloud, make it the first choice of start-ups, SMEs and even large Enterprises on the verge of a revamp.

More than 10000 businesses across multiple verticals have taken advantage of our unassailable trinity of Data Centers, Networks and Security services and conduct their business seamlessly from more than 1700 cities in India. Internationally, Sify has presence across North America, the United Kingdom and Singapore.

Sify, Sify Technologies, Sify Infinit Spaces and Sify Digital Services are registered trademarks of Sify Technologies Limited.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Sify undertakes no duty to update any forward-looking statements.

For a discussion of the risks associated with Sify’s business, please see the discussion under the caption “Risk Factors” in the company’s Annual Report on Form 20-F for the year ended March 31, 2025, which has been filed with the United States Securities and Exchange Commission and is available by accessing the database maintained by the SEC at www.sec.gov, and Sify’s other reports filed with the SEC.

For further information, please contact:

AstraZeneca's (AZN) Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at the European Society of Medical Oncology conference in Berlin.

That's the takeaway from Destiny-Breast11, one of several studies AstraZeneca presented. Patients with early-stage breast cancer were given Enhertu or a chemo cocktail. Enhertu works by sending toxic chemicals directly to the HER2 protein. HER2 shows up almost exclusively on cancer cells.

At the end of the study, more than 67% of Enhertu recipients showed no molecular signs of cancer in a tissue sample. That compares to roughly 56% of patients given the chemotherapy regimen. Notably, Enhertu carries fewer side effects than chemo due to how precise it is.

Treating early-stage breast cancer before it progresses is key to long-term survival, said David Fredrickson, AstraZeneca's executive vice president of oncology. Early-stage breast cancer carries a five-year survival rate of around 90%. By the advanced stages, just 30% of patients will still be alive after five years, he told Investor's Business Daily.

"So, the importance of that pathologic complete response, the importance of a high event-free survival cannot be overstated as it relates to the likelihood of being able to drive toward long-term durable outcomes," he said.

Enhertu's Powerful Sales Growth
Enhertu is one of AstraZeneca's rising oncology stars. Last year, the Daiichi Sankyo-partnered drug generated $1.98 billion in sales. Though the drug accounted for just 4% of AstraZeneca's total revenue, Enhertu sales grew 54%. That topped every other cancer drug in AstraZeneca's portfolio.

Now, the pharma giant is making a big push for Enhertu to be used in earlier-stage breast cancer patients.

In addition to the study in pre-surgery patients, AstraZeneca also laid out the results of its study called Destiny-Breast05. This tested Enhertu in patients who showed signs of cancer following surgery. Enhertu reduced the risk of cancer relapse by more than half compared to chemotherapy.

Importantly, 92% of patients given Enhertu were alive and free of invasive disease three years after receiving treatment.

Safety Profile Is Key
The safety profile, again, beat out traditional chemotherapy. Like chemotherapy, antibody drug conjugates, or ADCs, use toxic chemicals. But, while chemo is like a hammer, ADCs are like a laser. They send the toxic chemicals directly to proteins that show up on cancer cells.

That's particularly important in early-stage cancer, Fredrickson said.

"What you don't want to have is a serious adverse event that could have otherwise been avoided," he said. "And there were lower rates across multiple safety dimensions for the Enhertu arm than in others."

AstraZeneca is discussing next steps with global regulators, Fredrickson said. Both studies were Phase 3, meaning they are among the last the company will need to run to win Food and Drug Administration approval.

AstraZeneca Stock Is In A Buy Zone
AstraZeneca stock is currently lingering in a buy zone after breaking out of a lengthy cup-with-handle base with a buy point at 82.41, according to MarketSurge.

Shares have an improving IBD Digital Relative Strength Rating of 97. The RS Rating is a 1-99 measure of a stock's 12-month performance, pitted against all other stocks. Last week, AstraZeneca stock had an RS Rating of 77. Four weeks ago, the RS Rating was 52, an improvement from 30 three months ago.

Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.

YOU MAY ALSO LIKE:

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.

Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive.

Looking For The Next Big Stock Market Winners? Start With These 3 Steps

Find The Best Long-Term Investments With IBD Long-Term Leaders

Join IBD Live For Stock Ideas Each Morning Before The Open

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of HOM.U:CA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nutex (NUTX) To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Nutex between August 8, 2024 and August 14, 2025and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ:NUTX) in the United States District Court for the Southern District of Texas on behalf of all persons and entities who purchased or otherwise acquired Nutex securities between August 8, 2024 and August 14, 2025, both dates inclusive (the “Class Period”).Investors have until October 21, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the United States Securities and Exchange Commission ("SEC"); (vii) accordingly, Nutex's business and/or financial prospects were overstated; and (viii) as a result, Defendants' public statements were materially false and misleading at all relevant times. Next Steps:

If you purchased or otherwise acquired Nutex shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Nextech3D.AI (CSE:NTAR, OTCQX:NEXCF) CEO Evan Gappelberg spoke with Proactive about how artificial intelligence (AI) is reshaping the global events industry and the company’s latest developments in delivering a fully integrated AI-powered event tech platform. 

Gappelberg said, “AI is no longer just a nice to have. It's a new operating system for the global events industry.”  

He explained that Nextech3D.ai is deploying AI to streamline event operations, from registration and ticketing to matchmaking, floor mapping, and analytics. 

The company’s recent acquisition of Eventdex, alongside integration with its existing Map D platform, forms the foundation for this system.  

Features include AI-powered business matchmaking that books attendees' calendars based on their goals and behavior, as well as a multilingual AI assistant that acts as a 24/7 digital concierge.  

The assistant provides real-time guidance and information to attendees and also serves organizers with actionable data insights. 

Wayfinding and context-aware assistance are also part of the platform, reducing the need for on-site help desks.  

Gappelberg emphasized the mission to build “the world’s most intelligent, automated event tech platform,” and noted that blockchain-based ticketing is the next area of focus. 

The rollout is beginning with existing clients from both the Eventdex and Map D platforms, with plans to expand functionality over time. 

RADNOR, Pa., Oct. 18, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Fortinet, Inc. (“Fortinet”) (NASDAQ: FTNT) on behalf of those who purchased or otherwise acquired Fortinet common stock between November 8, 2024, and August 6, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is November 21, 2025.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered Fortinet losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/fortinet-inc?utm_source=Globe&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].

DEFENDANTS’ ALLEGED MISCONDUCT:
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Fortinet knew that the company’s refresh cycle would never be as lucrative as they represented because it consisted of old products that were a “small percentage” of Fortinet’s business; (2) Fortinet misrepresented and concealed that the company did not have a clear picture of the true number of FortiGate firewalls that could be upgraded; (3) while telling investors that the refresh would gain momentum over the course of two years, Fortinet misrepresented and concealed that the company had aggressively pushed through roughly half of the refresh in a period of just a few months, by the end of second quarter 2025; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/2-aYECTS09c

THE LEAD PLAINTIFF PROCESS:
Fortinet investors may, no later than November 21, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages Fortinet investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/fortinet-inc?utm_source=Globe&mktm=PR

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:     

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of LGCY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PAGP, EPD, WES either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Tronox (TROX) To Contact Him Directly To Discuss Their Options

If you purchased or acquired common stock in Tronox between February 12, 2025, to July 30, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tronox Holdings plc (“Tronox” or the “Company”) (NYSE:TROX) in the United States District Court for the District of Connecticut on behalf of all persons and entities who purchased or otherwise acquired Tronox common stock between February 12, 2025, to July 30, 2025, both dates inclusive (the “Class Period”).Investors have until November 3, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Tronox’s ability to forecast the demand for its pigment and zircon products or otherwise the true state of its commercial division, despite making lofty long-term projections, Tronox’s forecasting processes fell short as sales continued to decline and costs increased, ultimately, derailing the Company’s revenue projections.On July 30, 2025, Tronox announced its financial results for the second quarter of fiscal 2025, revealing a significant reduction in TiO2 sales for the quarter. The Company attributed the decline to “softer than anticipated coatings season and heightened competitive dynamics.” As a result of the setback in sales, defendants revised the Company’s 2025 financial outlook lowering its full-year revenue guidance and reducing its dividend by 60%.Following this news, Tronox’s common stock declined dramatically. From a closing market price of $5.14 per share on July 30, 2025, Tronox’s stock price fell to $3.19 per share on July 31, 2025, a decline of about 38% in the span of just a single day.
Next Steps:

If you purchased or otherwise acquired Tronox shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Palantir Technologies Inc. ("Palantir" or the "Company") (NASDAQ: PLTR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Palantir and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 3, 2025, media outlets reported that an internal U.S. Army memo described the NGC2 platform – a battlefield communication system developed by Palantir and Anduril Industries – as a "very high risk" due to security vulnerabilities that could allow adversaries to gain "persistent undetectable access" to the system. 

On this news, Palantir's stock price fell $13.98 per share, or 7.47%, to close at $173.07 per share on October 3, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Quantum Corporation ("Quantum" or the "Company")(NASDAQ: QMCO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Quantum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 3, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Quantum securities during the Class Period. A copy of the Complaint can be obtained at  www.pomerantzlaw.com .  

[Click here for information about joining the class action]

On June 30, 2025, Quantum disclosed in a filing with the U.S. Securities and Exchange Commission ("SEC") that it would postpone the filing of its Annual Report because it was in the process of reviewing its revenue recognition accounting practices. 

 On this news, Quantum's stock price fell $1.00 per share, or 10.03%, to close at $8.97 per share on July 1, 2025. 

Then, on August 8, 2025, Quantum filed a report with the SEC, announcing that the Company's financials for the third quarter of 2024 could not be relied upon and would be restated to show a new decrease of approximately $3.9 million in revenue, and that there were deficiencies in the Company's internal control over financial reporting and the Company's disclosure controls and procedures that constituted material weaknesses as of December 31, 2024 and March 31, 2025. 

On this news, Quantum's stock price fell $0.14 per share, or 1.85%, to close at $7.43 per share on August 11, 2025. 

Finally, on August 18, 2025, Quantum announced the resignation of its Chief Financial Officer Lewis Moorehead amid an internal accounting review related to its revenue recognition practices. 

On this news, Quantum's stock price fell $0.61 per share, or 8.2%, to close at $6.83 per share on August 19, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether LifeMD and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 27, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired LifeMD securities during the Class Period. A copy of the Complaint can be obtained a t www.pomerantzlaw.com .        

[Click here for information about joining the class action]

On August 5, 2025, after the market closed, the Company issued a press release entitled "LifeMD Reports Second Quarter 2025 Results."  This announcement quoted Chief Financial Officer Marc Benathen as stating that due to "some temporary challenges facing our Rex MD business," which he claimed were "largely resolved," that the Company was "revising our full year 2025 guidance for revenue and adjusted EBITDA to reflect the full-year impact of these issues, while still anticipating strong year-over-year growth in both metrics." 

On this news, LifeMD's stock price fell $5.31 per share, or 44.85%, to close at $6.53 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against VF Corporation ("VFC" or the "Company") (NYSE: VFC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether VFC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have until November 12, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired VFC securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com .

[Click here for information about joining the class action]

On May 21, 2025, VFC reported its fourth quarter and full-year fiscal 2025 financial results, highlighting a significant decline in the growth trajectory for its Vans brand, which fell from an 8% loss in the previous quarter to a 20% loss in the fourth quarter. VFC described these results and below-expectation guidance as "a direct effect of deliberately reduced revenue to eliminate unprofitable or unproductive businesses." 

Following this news, VFC's stock price fell $2.21 per share, or 15.8%, to close at $12.15 per share on May 21, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980 

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Jasper securities during the Class Period, you have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible Urticaria ("CIndU"), and Asthma. The Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s] that blocking this pathway may lead to depletion of these cells throughout the body, including in the lungs and in the skin, which could lead to significant clinical benefit for patients with mast-cell driven diseases such as asthma and chronic urticarias" and "[t]o that end, [Jasper is] focusing on advancing a portfolio of clinical programs in mast cell driven diseases." In 2024, to "strengthen [its] balance sheet and support development of briquilimab," Jasper completed an oversubscribed $50 million financing "with a syndicate of leading life science investors," purportedly "extending [its] cash runway through the third quarter of 2025."

In November 2023, the Company commenced a Phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of CSU (the "BEACON Study"). When announcing the first patient dosing in the BEACON Study, Jasper's Chief Executive Officer Defendant Ronald Martell stated, in relevant part, that he was "confident in the ability of our clinical organization to continue to execute at a high level as we advance briquilimab into clinical trials in CIndU and other mast cell-driven diseases." In December 2024, the Company commenced a Phase 1b/2a clinical study evaluating briquilimab in allergic asthma (the "ETESIAN Study"). In addition, Jasper has attempted to develop briquilimab as a one-time conditioning therapy for severe combined immunodeficiency ("SCID") patients undergoing a second stem cell transplant.

Under the Drug Supply Chain Security Act —a law enacted by Congress in 2013 designed to improve and ensure the safety of the U.S pharmaceutical supply chain—all prescription drugs must be labeled with a unique product identifier that includes, among other things, a "lot number." Drug "lots" are batches of a product that are manufactured, processed, packaged, or stored under the same conditions. If a medication is compromised, pharmaceuticals companies can use lot numbers to trace the affected batches and alert healthcare providers.

According to the Company, "[t]he manufacture of pharmaceuticals is subject to extensive [current Good Manufacturing Practices ("cGMP")] regulations, which impose various procedural and documentation requirements and govern all areas of record keeping, production processes and controls, personnel and quality control." Because Jasper does not currently own or operate any manufacturing facility, the Company relies on third-party contract manufacturing organizations to produce its drug candidates in purported "accordance with cGMP regulations for use in [its] clinical studies."

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On July 7, 2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question," that "[t]he Company is investigating the drug product lot in question and expects to have the results of that investigation in the coming weeks," and that Jasper was "taking steps to ensure that drug product from the lot in question is returned to the Company and that sites have drug product from other lots to continue dosing." Further, the press release revealed that the Company "has also determined that the drug product lot in question was used to treat participants enrolled in the ETESIAN [Study]. As a result, and in order to focus resources on advancing briquilimab in CSU, the Company is halting the study and pausing development in asthma." Finally, the press release stated that "the Company is halting development in SCID" and, contrary to its prior representation of having a strong balance sheet and a cash runway extending "through the third quarter of 2025," that Jasper "will be implementing a number of other cost cutting measures including a potential restructuring, to extend runway and reduce expenses."

On this news, Jasper's stock price fell $3.73 per share, or 55.1%, to close at $3.04 per share on July 7, 2025.

Market analysts were quick to comment on the Company's announcement. For example, on July 7, 2025, BMO Capital Markets published a report downgrading Jasper to market perform and lowering its price target from $6.77 per share to $4.00 per share (the "BMO Report"). The BMO Report stated, in relevant part, that "potential Briquilimab drug lot issues, coupled with existing uncertainty around dose-response [], will pressure the [Jasper] story moving forward" given, among other things, Jasper's "financing overhang" and market competition.

After the end of the Class Period, on July 9, 2025, the Company issued a press release entitled "Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway." The press release revealed that Jasper was reducing its workforce by approximately 50%, that "[i]n order to focus resources on the development of briquilimab in chronic urticaria, Jasper is halting its other clinical and preclinical programs," and that Defendant Edwin Tucker was departing his role as the Company's Chief Medical Officer effective August 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In